Courtney Marabella

Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma.

The CAR T-cell therapy elicited an overall response rate (ORR) of 97.9% at a median follow-up of 18 months.

A novel combination immunotherapy enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.

Faith E. Davies, MD, discussed the potential of CAR T-cell therapies for the treatment of multiple myeloma.

A single infusion of KTE-X19, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

CAR natural killer T cells that co-express GD2 and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden